CN107022350A - 一种荧光造影材料及其制备方法与应用 - Google Patents
一种荧光造影材料及其制备方法与应用 Download PDFInfo
- Publication number
- CN107022350A CN107022350A CN201710261653.9A CN201710261653A CN107022350A CN 107022350 A CN107022350 A CN 107022350A CN 201710261653 A CN201710261653 A CN 201710261653A CN 107022350 A CN107022350 A CN 107022350A
- Authority
- CN
- China
- Prior art keywords
- fluoroscopic visualization
- flavonoids
- visualization material
- fluorescent dye
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 52
- 238000012800 visualization Methods 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 39
- 229930003935 flavonoid Natural products 0.000 claims abstract description 36
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 36
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 15
- -1 hydroxyl butyl Chemical group 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- 125000001424 substituent group Chemical group 0.000 claims abstract description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 18
- 239000012452 mother liquor Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- 230000002792 vascular Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 11
- 235000005513 chalcones Nutrition 0.000 claims description 11
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000004043 dyeing Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000012460 protein solution Substances 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 238000005415 bioluminescence Methods 0.000 claims description 5
- 230000029918 bioluminescence Effects 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 102000005686 Serum Globulins Human genes 0.000 claims description 3
- 108010045362 Serum Globulins Proteins 0.000 claims description 3
- 108010090932 Vitellogenins Proteins 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 239000010413 mother solution Substances 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 238000006862 quantum yield reaction Methods 0.000 abstract description 7
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 description 14
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 11
- 241000252212 Danio rerio Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229960002143 fluorescein Drugs 0.000 description 10
- 239000000975 dye Substances 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002601 radiography Methods 0.000 description 7
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000007447 staining method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000005204 hydroxybenzenes Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供了一种荧光造影材料及其制备方法与应用,本发明荧光造影材料由高荧光量子产率的类黄酮荧光染料与高生物相容性蛋白质内的疏水空腔结合而成,所述类黄酮荧光染料的结构通式如下:其中R1、R2、R3、R4、R5、R6是不同的取代基,R1、R2、R3、R4为H、羟基(‑OH)、羟甲基(‑OCH3)或二甲胺基(‑N(CH3)2),R5和R6为甲基(‑CH3)、乙基(‑CH2CH3)、丁基(‑CH2CH2CH2CH3)或羟丁基(‑CH2CH2CH2CH2OH),本发明荧光造影材料具有低生物毒性、高荧光量子产率、高荧光稳定性、高水溶性以及高生物相容性特点。
Description
技术领域
本发明涉及荧光材料领域,尤其涉及一种荧光造影材料及其制备方法与应用。
背景技术
长久以来,与血管相关的疾病非常常见。以眼底血管为例,临床上常见诸如糖尿病性视网膜病变、视网膜血管炎、血管阻塞性疾病、脉络膜血管瘤,急性视网膜坏死、以及各种病因的黄斑病等等。由于眼底血管在眼球内部,用普通的光学技术难以直接观察病灶。利用眼底血管荧光造影技术,能够对眼底部的整个血管脉络组织进行精确成像,以帮助医生对病人的病患做出正确的诊断。
现在国际上通用的眼底血管荧光造影术主要是荧光素染色法(FluoresceinFundus Angiography,FFA法)。医生从病人肘静脉快速(约5秒)推入20%荧光素钠水溶液约3ml,在短时间内用荧光检测仪器对患者眼底血管进行荧光成像拍摄。然而,现有的荧光素染料有许多缺点:(1)荧光素对人体毒副作用大,超过4%病人出现恶心呕吐反应,0.2%病人现严重疼痛症状,少数会有过敏性休克,因而必须进行皮试实验。(2)荧光素在体内代谢速度比较慢,荧光素注射后出现皮肤、结膜发黄,尿液呈黄色,该染黄现象持续24-48小时,代谢主要经肾脏及胆道,会造成轻度肝肾功能损伤,相关功能不全者禁用。(3)荧光素法成像时间短,静脉注射后2分钟至几小时,脉络膜毛细血管中的荧光素会发生严重渗漏,致使周围组织与巩膜着色。
因此,现有技术还有待于改进和发展。
发明内容
鉴于上述现有技术的不足,本发明的目的在于提供一种荧光造影材料及其制备方法与应用,旨在解决现有荧光素染色法中,荧光素对人体毒副作用大、荧光素在体内代谢速度比较慢、荧光素法成像时间短的问题。
本发明的技术方案如下:
一种荧光造影材料,其中,由类黄酮荧光染料与蛋白质结合而成。
所述的荧光造影材料,其中,所述类黄酮荧光染料的结构通式如下所示:
其中,R1、R2、R3、R4、R5、R6是不同的取代基,R1、R2、R3、R4为H、羟基、羟甲基或二甲胺基,R5和R6为甲基、乙基、丁基或羟丁基。
所述的荧光造影材料,其中,所述蛋白质为人血清白蛋白、牛血清白蛋白、血红蛋白、脂蛋白、转运蛋白、酪蛋白、卵黄原蛋白、胶质蛋白、血清球蛋白、人血清离心样本中的一种。
所述的荧光造影材料,其中,所述类黄酮荧光染料与蛋白质的重量比为1:10-1:100000。
一种如上任一所述的荧光造影材料的制备方法,其中,包括:
步骤A、将所述类黄酮荧光染料溶于第一溶剂中,配制成10-6-10-2摩尔/升的类黄酮荧光染料母液;
步骤B、将所述蛋白质溶于第二溶剂中,配制成0.01-1000毫克/毫升的蛋白质溶液母液;
步骤C、将1-100微升的所述类黄酮荧光染料母液滴加到1-100毫升的所述蛋白质溶液母液中,并在滴加过程中对所述蛋白质溶液母液施以震荡或搅拌5-120分钟,得到荧光造影材料。
所述的荧光造影材料的制备方法,其中,所述步骤A中,所述第一溶剂为甲醇、乙醇、DMSO中的一种。
所述的荧光造影材料的制备方法,其中,所述步骤B中,所述第二溶剂为水、生理盐水、磷酸盐缓冲溶液、血清离心上清液中的一种。
所述的荧光造影材料的制备方法,其中,所述步骤A中,所述类黄酮荧光染料的制备方法包括:
步骤A1、将临羟基苯乙酮和对氨基苯甲醛加入到乙醇中,然后冷却,逐滴加入氢氧化钠溶液,搅拌8-12h后,加入到冰水中,再用盐酸中和,最后于冰箱中静置过夜,过滤干燥,得到中间体查尔酮;
步骤A2、将所述中间体查尔酮溶于四氢呋喃中,然后加入乙醇,并逐滴加入氢氧化钾溶液,然后冷却,接着滴加双氧水溶液,室温搅拌40-60小时,再用盐酸中和,最后过滤干燥并重结晶,获得类黄酮荧光染料。
一种如上任一所述的荧光造影材料的应用,其中,应用于生物荧光成像。
所述的荧光造影材料的应用,其中,所述生物荧光成像为细胞样本染色、组织染色、血管系统荧光造影中的一种。
有益效果:本发明提供了一种荧光造影材料,所述荧光造影材料由高荧光量子产率的类黄酮荧光染料与高生物相容性蛋白质内的疏水空腔结合而成,其具有低生物毒性、高荧光量子产率、高荧光稳定性、高水溶性以及高生物相容性特点,可应用于细胞染色、组织标记、以及血管荧光成像。
附图说明
图1为实施例4中利用FL341-HSA配合物对人体干细胞的染色图。
图2为实施例5中利用FL341-HSA配合物对血管内皮组织的染色图。
图3为实施例6中利用FL341-HSA配合物对斑马鱼眼部外周血管第一视角的染色图。
图4为实施例6中利用FL341-HSA配合物对斑马鱼眼部外周血管第二视角的染色图。
图5为实施例6中利用FL341-HSA配合物对斑马鱼眼底血管第一视角的染色图。
图6为实施例6中利用FL341-HSA配合物对斑马鱼眼底血管第二视角的染色图。
具体实施方式
本发明提供一种荧光造影材料及其制备方法与应用,为使本发明的目的、技术方案及效果更加清楚、明确,以下对本发明进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明提供一种荧光造影材料的较佳实施例,其中,由类黄酮荧光染料与蛋白质结合而成。具体地,本发明所述荧光造影材料是由高荧光量子产率的类黄酮荧光染料与高生物相容性蛋白质内的疏水空腔结合而成的,所述类黄酮荧光染料的结构通式如下所示:
其中,R1、R2、R3、R4、R5、R6是不同的取代基,R1、R2、R3、R4为H、羟基(-OH)、羟甲基(-OCH3)或二甲胺基(-N(CH3)2),R5和R6为甲基(-CH3)、乙基(-CH2CH3)、丁基(-CH2CH2CH2CH3)或羟丁基(-CH2CH2CH2CH2OH)。
本发明利用高荧光量子产率的类黄酮荧光染料与高生物相容性蛋白质内疏水空腔结合,制备得到了具有低生物毒性、高荧光量子产率、高荧光稳定性、高水溶性以及高生物相容性的荧光造影材料,所述荧光造影材料可应用于细胞染色、组织标记、以及血管荧光成像。
本发明还提供了一种如上任一所述的荧光造影材料的制备方法较佳实施例,其中,包括:
步骤A、将所述类黄酮荧光染料溶于第一溶剂中,配制成10-6-10-2摩尔/升的类黄酮荧光染料母液;
优选地,所述第一溶剂可以为但不限于甲醇、乙醇、DMSO等中的一种。
所述步骤A中,所述类黄酮荧光染料的制备方法包括:
步骤A1,制备中间体查尔酮:将50毫摩尔的含不同R1、R2、R3、R4取代基的临羟基苯乙酮和50毫摩尔的含不同R5、R6取代基的对氨基苯甲醛加入到100-500毫升乙醇中,然后置于冰水浴中冷却,逐滴加入10-100毫升的20%wt的氢氧化钠溶液,搅拌8-12h(如10小时)后,倒入到100-1000毫升的冰水中,用浓度为3摩尔/升的稀盐酸中和,中和完毕后,将反应液置于冰箱中静置过夜,冰箱温度设置在0-10℃之间,过夜时间为8-12小时,如10小时,将沉淀过滤干燥,即获得中间体查尔酮,反应方程式如下:
优选的,上述步骤A1中,乙醇用量为200毫升,氢氧化钠溶液用量为50毫升,冰水用量为500毫升。
步骤A2,制备类黄酮荧光染料:取10毫摩尔的含不同R1、R2、R3、R4、R5、R6取代基的中间体查尔酮溶于10毫升四氢呋喃,然后加入10-100毫升的乙醇溶液,并逐滴加入5-50毫升的质量分数为20%的氢氧化钾溶液,加入完成后将反应液用冰水浴冷却,接着滴加5-30毫升30%wt的双氧水溶液,室温搅拌40-60小时(如48小时),用浓度为1摩尔/升的稀盐酸中和,将沉淀过滤干燥后,在劣溶剂中重结晶,获得类黄酮荧光染料,反应方程式如下:
优选的,上述步骤A2中,乙醇用量为50毫升,氢氧化钠溶液用量为10毫升,双氧水溶液用量为20毫升。
步骤B、将所述蛋白质溶于第二溶剂中,配制成0.01-1000毫克/毫升的蛋白质溶液母液;
优选地,所述第二溶剂可以为但不限于水、生理盐水、磷酸盐缓冲溶液(pH=7.4)、血清离心上清液等中的一种。
优选地,所述蛋白质可以为但不限于人血清白蛋白、牛血清白蛋白、血红蛋白、脂蛋白、转运蛋白、酪蛋白、卵黄原蛋白、胶质蛋白、血清球蛋白、人血清离心样本等中的一种。
步骤C、将1-100微升的所述类黄酮荧光染料母液缓慢滴加到1-100毫升的所述蛋白质溶液母液中,并在滴加过程中对所述蛋白质溶液母液施以震荡或搅拌,震荡或搅拌的时间为5-120分钟,得到荧光造影材料。
本发明还提供了一种如上任一所述荧光造影材料的应用,其中,将所述荧光造影材料应用于生物荧光成像,例如细胞染色、组织标记、以及血管荧光成像等。本发明所述荧光造影材料置于冰箱中保存,使用时将荧光造影材料缓慢加热至37度。本发明方法制备的小分子染料-蛋白质配合物(即所述荧光造影材料),可以对常见细胞样本、血管壁组织、生物组织切片、脊椎鱼类、以及哺乳动物的血管系统实施荧光造影,荧光造影的染色方式为滴加、涂抹、注射中的一种,详细的配制流程与染色方式在实施例中阐述。
下面通过实施例对本发明进行详细说明。
实施例1
类黄酮染料FL341(结构式如下)的制备步骤如下:
将50毫摩尔的1-乙酰基-2-羟基-4,5-二羟甲基苯和50毫摩尔的对二甲氨基苯甲醛加入含200毫升乙醇的反应瓶中,将反应瓶放于冰水浴中冷却,逐滴加入50毫升的20%wt的氢氧化钠溶液,搅拌10小时后,倒入500毫升的冰水中,用浓度为3摩尔/升的稀盐酸中和。中和完毕后,将反应液置于冰箱中静置过夜,然后将得到的沉淀过滤干燥,即获得查尔酮粗产物。取10毫摩尔的查尔酮粗产物溶于10毫升四氢呋喃,然后加入50毫升的乙醇溶液,并逐滴加入10毫升的质量分数为20%的氢氧化钾溶液,加入完成后将反应液用冰水浴冷却,接着滴加20毫升30%wt的双氧水溶液,室温搅拌48小时,用浓度为1摩尔/升的稀盐酸中和,将得到的沉淀过滤干燥后,在冰乙醇-正乙烷中重结晶,获得类黄酮荧光染料FL341,其结构式如下所示。
实施例2
类黄酮染料FL339的制备步骤如下:
将50毫摩尔的1-乙酰基-2-羟基-6-羟甲基苯和50毫摩尔的对二乙氨基苯甲醛加入到含250毫升乙醇的反应瓶中,将反应瓶放于冰水浴中冷却,逐滴加入40毫升的20%wt的氢氧化钠溶液,搅拌12小时后,倒入400毫升的冰水中,用浓度为3摩尔/升的稀盐酸中和。中和完毕后,将反应液置于冰箱中静置过夜,将沉淀过滤干燥,即获得查尔酮粗产物。取10毫摩尔的查尔酮粗产物溶于10毫升四氢呋喃,然后加入40毫升的乙醇溶液,并逐滴加入15毫升的质量分数为20%的氢氧化钾溶液,加入完成后将反应液用冰水浴冷却,接着滴加20毫升30%wt的双氧水溶液,室温搅拌48小时,用浓度为1摩尔/升的稀盐酸中和,将沉淀过滤干燥后,在冰乙醇中重结晶,获得类黄酮荧光染料FL339,其结构式如下所示。
实施例3
FL341-HSA配合物荧光造影材料的制备步骤如下:
将3.41毫克类黄酮染料FL341溶于10毫升乙醇,均匀搅拌至完全溶解,配制成10-3摩尔/升的FL341类黄酮荧光染料母液;将100毫克人血清白蛋白(HSA)溶于10毫升磷酸盐缓冲溶液(pH=7.4)中,加热37摄氏度,均匀搅拌至完全溶解,配制得10毫克/毫升的HSA蛋白质溶液母液;将100微升的FL341类黄酮荧光染料母液缓慢滴入至10毫升的HSA蛋白质溶液母液中,均匀搅拌为20分钟,直至溶液至较透明,制备得FL341-HSA配合物荧光造影材料。
实施例4
利用FL341-HSA配合物进行细胞染色。
将100微升的FL341-HSA配合物荧光造影材料溶液滴入1mL人体干细胞培养液中,在培养箱中培养15分钟后,用PBS水溶液清洗细胞3次。如图1所示,由荧光显微镜可以观察到,人体干细胞被荧光染料成功染色。
实施例5
利用FL341-HSA配合物进行组织染色。
将培养好的血管内皮组织,用PBS缓冲溶液清洗3次,然后置于培养皿中,将200微升的FL341-HSA配合物荧光造影材料溶液滴入培养皿,培养20分钟后,再用PBS水溶液清洗细胞3次。如图2所示,由荧光显微镜可以观察到,血管内皮组织被荧光染料成功染色。
实施例6
利用FL341-HSA配合物对斑马鱼眼底血管进行荧光成像。
将3dpf的斑马鱼用Agarose水凝胶侧位固定于培养皿上,利用微注射技术,将20微升的FL341-HSA配合物荧光造影材料溶液注射入斑马鱼卵黄囊的血管区,注射速率小于10微升/分钟,注射完成后,将载有斑马鱼培养皿置于28摄氏度的恒温水中,直至水凝胶完全溶解。等待约10分钟后,将斑马鱼取出,对斑马鱼眼底血管实施激光共聚焦荧光成像。如图3-6所示,斑马鱼眼外环血管以及眼底血管,皆呈现明亮的荧光,而其他组织的荧光强度非常弱,证明该配合物能够选择性的对血管系统染色。
综上所述,本发明提供的一种荧光造影材料及其制备方法与应用,所述荧光造影材料是小分子染料和高生物相容性蛋白质构成的配合物,其中小分子染料为高荧光量子产率的类黄酮荧光染料,其与高生物相容性蛋白质内的疏水空腔结合;本发明利用类黄酮荧光染料的低生物毒性,解决了现有的荧光素染色法对人体产生较严重副作用的问题,同时利用类黄酮荧光染料的高荧光量子产率、高荧光稳定性和高生物相容性蛋白质的高水溶性、高生物相容性,使得本发明的荧光造影材料能够很好地应用于临床。
应当理解的是,本发明的应用不限于上述的举例,对本领域普通技术人员来说,可以根据上述说明加以改进或变换,所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (10)
1.一种荧光造影材料,其特征在于,由类黄酮荧光染料与蛋白质结合而成。
2.根据权利要求1所述的荧光造影材料,其特征在于,所述类黄酮荧光染料的结构通式如下所示:
其中,R1、R2、R3、R4、R5、R6是不同的取代基,R1、R2、R3、R4为H、羟基、羟甲基或二甲胺基,R5和R6为甲基、乙基、丁基或羟丁基。
3.根据权利要求1所述的荧光造影材料,其特征在于,所述蛋白质为人血清白蛋白、牛血清白蛋白、血红蛋白、脂蛋白、转运蛋白、酪蛋白、卵黄原蛋白、胶质蛋白、血清球蛋白、人血清离心样本中的一种。
4.根据权利要求1所述的荧光造影材料,其特征在于,所述类黄酮荧光染料与蛋白质的重量比为1:10-1:100000。
5.一种如权利要求1-4任一所述的荧光造影材料的制备方法,其特征在于,包括:
步骤A、将所述类黄酮荧光染料溶于第一溶剂中,配制成10-6-10-2摩尔/升的类黄酮荧光染料母液;
步骤B、将所述蛋白质溶于第二溶剂中,配制成0.01-1000毫克/毫升的蛋白质溶液母液;
步骤C、将1-100微升的所述类黄酮荧光染料母液滴加到1-100毫升的所述蛋白质溶液母液中,并在滴加过程中对所述蛋白质溶液母液施以震荡或搅拌5-120分钟,得到荧光造影材料。
6.根据权利要求5所述的荧光造影材料的制备方法,其特征在于,所述步骤A中,所述第一溶剂为甲醇、乙醇、DMSO中的一种。
7.根据权利要求5所述的荧光造影材料的制备方法,其特征在于,所述步骤B中,所述第二溶剂为水、生理盐水、磷酸盐缓冲溶液、血清离心上清液中的一种。
8.根据权利要求5所述的荧光造影材料的制备方法,其特征在于,所述步骤A中,所述类黄酮荧光染料的制备方法包括:
步骤A1、将临羟基苯乙酮和对氨基苯甲醛加入到乙醇中,然后冷却,逐滴加入氢氧化钠溶液,搅拌8-12h后,加入到冰水中,再用盐酸中和,最后于冰箱中静置过夜,过滤干燥,得到中间体查尔酮;
步骤A2、将所述中间体查尔酮溶于四氢呋喃中,然后加入乙醇,并逐滴加入氢氧化钾溶液,然后冷却,接着滴加双氧水溶液,室温搅拌40-60小时,再用盐酸中和,最后过滤干燥并重结晶,获得类黄酮荧光染料。
9.一种如权利要求1-4任一所述的荧光造影材料的应用,其特征在于,应用于生物荧光成像。
10.根据权利要求9所述的荧光造影材料的应用,其特征在于,所述生物荧光成像为细胞样本染色、组织染色、血管系统荧光造影中的一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710261653.9A CN107022350A (zh) | 2017-04-20 | 2017-04-20 | 一种荧光造影材料及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710261653.9A CN107022350A (zh) | 2017-04-20 | 2017-04-20 | 一种荧光造影材料及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107022350A true CN107022350A (zh) | 2017-08-08 |
Family
ID=59527573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710261653.9A Pending CN107022350A (zh) | 2017-04-20 | 2017-04-20 | 一种荧光造影材料及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107022350A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110204920A (zh) * | 2019-05-05 | 2019-09-06 | 深圳大学 | 一种黄酮荧光染料及其制备方法与应用 |
CN113189068A (zh) * | 2021-04-27 | 2021-07-30 | 华南农业大学 | 一种基于荧光分析的农药检测方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001870A (zh) * | 2004-06-16 | 2007-07-18 | 通用电气医疗集团股份有限公司 | 基于肽的化合物 |
CN104189925A (zh) * | 2014-08-28 | 2014-12-10 | 中国科学院宁波材料技术与工程研究所 | 一种新型造影材料、其制备方法及应用 |
CN104487098A (zh) * | 2012-07-20 | 2015-04-01 | 佳能株式会社 | 光声成像用造影剂 |
CN104984370A (zh) * | 2014-08-13 | 2015-10-21 | 中国科学院宁波材料技术与工程研究所 | 一种造影材料、其制备方法及应用 |
US20150369812A1 (en) * | 2014-06-16 | 2015-12-24 | Yi Pang | Flavonoid compounds of low toxicity for biological imaging applications |
CN105542754A (zh) * | 2015-12-31 | 2016-05-04 | 深圳大学 | 一种黄酮基荧光分子探针及其制备方法与应用 |
CN105985431A (zh) * | 2015-03-23 | 2016-10-05 | 佳能株式会社 | 结合近红外染料的转铁蛋白及含该蛋白的光声成像用造影剂 |
-
2017
- 2017-04-20 CN CN201710261653.9A patent/CN107022350A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001870A (zh) * | 2004-06-16 | 2007-07-18 | 通用电气医疗集团股份有限公司 | 基于肽的化合物 |
CN104487098A (zh) * | 2012-07-20 | 2015-04-01 | 佳能株式会社 | 光声成像用造影剂 |
US20150369812A1 (en) * | 2014-06-16 | 2015-12-24 | Yi Pang | Flavonoid compounds of low toxicity for biological imaging applications |
CN104984370A (zh) * | 2014-08-13 | 2015-10-21 | 中国科学院宁波材料技术与工程研究所 | 一种造影材料、其制备方法及应用 |
CN104189925A (zh) * | 2014-08-28 | 2014-12-10 | 中国科学院宁波材料技术与工程研究所 | 一种新型造影材料、其制备方法及应用 |
CN105985431A (zh) * | 2015-03-23 | 2016-10-05 | 佳能株式会社 | 结合近红外染料的转铁蛋白及含该蛋白的光声成像用造影剂 |
CN105542754A (zh) * | 2015-12-31 | 2016-05-04 | 深圳大学 | 一种黄酮基荧光分子探针及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
ALEXANDER SYTNIK ET AL.,: ""Interplay between excited-state intramolecular proton transfer and charge transfer in flavonols and their use as protein-binding-site fluorescence probes"", 《PROC. NATL. ACAD. SCI. USA》 * |
ANDREY S. KLYMCHENKO ET AL.,: ""Resolution of Cys and Lys labeling of a-crystallin with site-sensitive fluorescent 3-hydroxyflavone dye"", 《ANALYTICAL BIOCHEMISTRY》 * |
LUCAS MCDONALD ET AL.,: ""Fluorescent flavonoids for endoplasmic reticulum cell imaging"", 《J. MATER. CHEM. B》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110204920A (zh) * | 2019-05-05 | 2019-09-06 | 深圳大学 | 一种黄酮荧光染料及其制备方法与应用 |
CN113189068A (zh) * | 2021-04-27 | 2021-07-30 | 华南农业大学 | 一种基于荧光分析的农药检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bandamwar et al. | Fluorescein staining and physiological state of corneal epithelial cells | |
Stalmans et al. | Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent | |
CN105950700B (zh) | 一种真菌荧光染色剂 | |
Lepiller et al. | Imaging of nitric oxide in a living vertebrate using a diaminofluorescein probe | |
Stalmans et al. | Trypan blue not toxic for retinal pigment epithelium in vitro | |
SIDMAN et al. | Histochemical observations on rods and cones in retinas of vertebrates | |
McMenamin | Optimal methods for preparation and immunostaining of iris, ciliary body, and choroidal wholemounts | |
CN107022350A (zh) | 一种荧光造影材料及其制备方法与应用 | |
Stalmans et al. | Double vital staining using trypan blue and infracyanine green in macular pucker surgery | |
Yip et al. | [Ca2+] i in rat afferent arteriole during constriction measured with confocal fluorescence microscopy | |
Ooi et al. | The structural effect of intravitreal Brilliant blue G and Indocyanine green in rats eyes | |
Brazile et al. | Lamina cribrosa capillaries straighten as intraocular pressure increases | |
CN115200963A (zh) | 一种油红o染色液及油红o染色方法 | |
CN109387416A (zh) | 一种用于制片染色一体机的巴氏染色液 | |
Jackson et al. | An experimental method for testing novel retinal vital stains | |
Schweitzer | Metabolic mapping | |
CN108148887A (zh) | 用于检测微生物感染的染色剂组合物及其制备方法 | |
Peters et al. | Systematic evaluation of ICG and trypan blue related effects on ARPE-19 cells in vitro | |
Hackett et al. | A method for differential staining of bovine spermatozoa after extension in sterile milk | |
CN105524608A (zh) | 一种荧光探针ah及其制备和应用 | |
Chacarov et al. | A one-act differential stain of the acrosome with active dyes | |
JP7042751B2 (ja) | 眼科用染料組成物 | |
Li et al. | High‐Resolution Imaging of the Ocular Vasculature of Conjunctivitis in Mice Using Highly Bright Polymer Dots | |
Querques et al. | Retinal toxicity of indocyanine green | |
Blattner et al. | Teratogenic Changes in Early Chick Embryos Following Administration of Antitumor Agent.(Azaserine) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170808 |